Compare Enveric Biosciences Inc (ENVB) vs NVR Inc. Common Stock (NVR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs NVR Inc. Common Stock — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $6.09M), while NVR Inc. Common Stock trades at $6,031.23 (market cap $15.28B). The key difference: NVR Inc. Common Stock is far larger — about 2509× Enveric Biosciences Inc's market cap, and NVR Inc. Common Stock is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and NVR Inc. Common Stock for 0 Days on average.
| ENVB | NVR | |
|---|---|---|
Market Cap | $6.09M | $15.28B |
Volume | 163,910 | 53,948 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $8.10K |
52-Week Low | $1.27 | $5.56K |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | -$2.21M | $15.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.40, down 4.76% on the day, with a bearish technical outlook from moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS estimates in recent quarters. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook is mixed; analyst consensus is 75% buy with potential from its drug pipeline, but high financial losses and negative ROE/ROA pose significant risks. Investment opportunity hinges on clinical success, while near-term volatility and cash burn are key concerns for stockholders.
NVR trades at $5,797.61, up 0.83% today, with a P/E of 15.07 and P/S of 1.79. Recent earnings missed estimates in Q1 and Q2 2026, with revenue and net income projected to decline in 2026. The stock faces headwinds from margin pressure and softer homebuyer demand, as highlighted by Zacks naming it Bear of the Day on October 9, 2026. Despite this, strong profitability metrics like a 31.54% ROE and consistent cash flow from operations support its financial resilience.
The outlook is cautious due to earnings misses and a projected revenue drop, but the asset-light model and share buybacks provide stability. Risks include mortgage rate sensitivity and competitive pressures, while analyst consensus leans neutral with a $6,550 price target. Patient investors may find value if housing demand recovers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About NVR Inc. Common Stock
NVR Inc. is a homebuilder operating through homebuilding and mortgage banking segments, building single-family homes, townhomes, and condominiums under the Ryan Homes, NVHomes, and Heartland Homes brands. It uses a land-light model, acquiring lots through third-party option agreements rather than holding large land inventories, and provides mortgage and title services through NVR Mortgage.
Read more on NVR →
